Novel methods to treat glaucoma

Credit: CC0 Public Domain

Glaucoma is characterized by degeneration of retinal ganglion cells, leading to irreversible vision loss. Currently, the only treatable glaucoma risk factor is increased intraocular pressure. While lowering this pressure can slow vision loss, it does not completely halt progression of the disease. Therefore, determining more direct mechanisms to prevent retinal cell degeneration are essential.

Rebecca Sappington, Ph.D., and colleagues show that increasing cGMP—part of a signaling pathway that was previously found to regulate —protects retinal ganglion .

The investigators used mouse models of glaucoma, isolated mouse retinas, and cultured to explore cGMP action. In the mouse models, they found that inhibiting the enzyme that breaks down cGMP prevented retinal ganglion cell degeneration without altering intraocular pressure. In cultured cells, addition of a cGMP-like compound blocked cell death pathways.

Reporting in Neurobiology of Disease, this study suggests a novel glaucoma treatment that utilizes a direct cellular target and is independent of intraocular pressure.

Explore further

Biomarkers facilitate early detection of glaucoma

More information: Lauren K. Wareham et al. Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration, Neurobiology of Disease (2018). DOI: 10.1016/j.nbd.2018.09.002
Journal information: Neurobiology of Disease

Citation: Novel methods to treat glaucoma (2018, November 9) retrieved 10 August 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors